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Simple Summary: The majority of hereditary pheochromocytoma and paraganglioma (PPGL) is
caused by germline mutations in the SDHB, SDHC, or SDHD genes, which encode three (SDHB,
SDHC, SDHD) of five subunits of succinate dehydrogenase (SDH) enzyme (SDHA, SDHDB, SDHC,
SDHD, SDHAF2). The inactivation of any of the SDHx genes leads to the proteolysis of SDH. This can
be detected with negative immunohistochemistry (IHC) for SDHB. However, there is no consensus
of the interpretation of “weakly positive” staining. Hence, we carried out a retrospective single
centre study comprising 58 patients to evaluate the efficacy of using SDHB IHC for detecting SDHx
mutation in PPGL cases. Our analyses revealed that SDHB-negative IHC is a cost-effective and
reliable method to predict SDHx mutations in the Korean population. Nonetheless, in the case of
weakly positive staining, an additional gene study should be considered.
Abstract: The most common genetic backgrounds of hereditary paraganglioma and pheochromocy-
toma (PPGL) are SDHx germline mutations. Given the fact that the immunohistochemistry (IHC)
result for SDHB is always negative regardless of the type of SDHx mutation, we aimed to evaluate
the efficacy of using SDHB IHC for screening SDHx mutations in PPGL cases. In total, 52 patients
who underwent surgery for PPGL treatment between 2006 and 2020 and underwent genetic analysis
at diagnosis were included. Tissue microarrays (TMAs) were constructed with PPGL tissues and
IHC for SDHB was performed on TMA sections. All 10 patients with SDHB-negative IHC contained
SDHB or SDHD mutations. The genetic test results of patients with SDHB-weakly positive IHC
varied (one SDHB, two RET, one VHL, and three unknown gene mutations). There were no SDHx
mutations in the SDHB-positive IHC group. Six patients with weakly positive SDHB IHC with
primarily unknown genetic status were re-called and underwent next-generation sequencing. None
of them had SDHx mutations. In conclusion, SDHB-negative IHC is a cost-effective and reliable
method to predict SDHx mutations. However, in the case of weakly positive SDHB staining, an
additional gene study should be considered.
Keywords: pheochromocytoma; sympathetic paraganglioma; genetic screening; immunohistochem-
istry; SDHB
1. Introduction
Pheochromocytomas and sympathetic paragangliomas (PPGLs) are rare catecholamine-
secreting tumours arising from chromaffin tissue of the adrenal medulla or extra-adrenal
sympathetic paraganglia [1]. The classical “rule of 10”, which states that 10% of these
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tumours are associated with a familial syndrome, has been invalidated recently. Rather,
PPGL shows the highest degree of heritability in human neoplasms, up to 40% [2]. Al-
though a sporadic form exists, the vast majority of PPGLs occur as a manifestation of
inherited tumour syndromes such as multiple endocrine neoplasia type 2 (MEN2; RET
gene), von Hippel–Lindau (VHL) disease (VHL gene), neurofibromatosis type 1 (NF1; NF1
gene), and hereditary PPGL [3–6]. Among these, hereditary PPGL is the most common
condition and is mostly caused by germline mutations in the SDHB, SDHC, or SDHD
genes [7,8]. The rich genetic background of these tumours, which is even found in 12% of
apparently sporadic PPGLs [9], has led to recommendations that every patient with PPGL
should be considered for genetic testing [10]. Gene study allows the identification of other
manifestations of hereditary tumour syndromes, verifying the mutations associated with a
high risk of metastasis such as SDHB mutation, and the screening of at-risk probands [10].
The most common germline mutations are SDHB and SDHD genes, which account
for 6–9% of sporadic PPGL and more than 80% of familial aggregations of PPGL [10,11].
PPGLs related to mutations of SDHB and SDHD genes usually occur early in life and
are often multifocal [12]. Strong association between metastasis and SDHB mutation was
also reported [7,13]. The penetrance of SDHB and SDHD germline mutations is known
to be approximately 50% in patients in their 30s [6]. This incomplete penetrance, along
with maternal imprinting (SDHD), the phenotypic heterogeneity of the disease, lack of
family information, overlap in age distribution between hereditary and sporadic cases, de
novo mutations, and insufficient awareness of clinicians, can lead to the underdiagnosis of
hereditary PPGL [8].
Nowadays, next-generation sequencing (NGS) panels are widely used to evaluate
germline mutation status. Although the introduction of NGS greatly reduced the cost and
time of genetic testing compared to those of conventional Sanger sequencing [14], it is still
meaningful to find a cost-effective screening tool that can detect SDHx mutation, which
accounts for the largest portion of hereditary PPGL.
Succinate dehydrogenase (SDH) is a protein complex that plays an important role in
the electron transport chain and the Krebs cycle [15]. The SDH complex is composed of
two anchoring subunits (SDHC and SDHD) and two catalytic subunits (SDHA and SDHB).
Each subunit is transcribed from SDHC, SDHD, SDHA, and SDHB genes, respectively.
Remarkably, immunohistochemistry (IHC) for SDHB becomes negative if any component
of the SDH complex is lost due to mutations of SDHx genes [16]. Therefore, efforts to
validate IHC for SDHB as a cost-effective screening tool for hereditary PPGL have been
made. Since van Nederveen et al. and Gill et al. reported the high sensitivity and specificity
of negative IHC for SDHB to diagnose hereditary PPGL in the late 2000s [8,17], several
similar studies have been published [17–20]. The fourth edition of the World Health
Organization’s (WHO) classification of endocrine tumours mentioned negative IHC for
SDHB as an important marker for this group of tumours [21].
However, the interpretation of “weakly positive” staining of SDHB is still in debate.
In this first study in South Korea, we conducted IHC for SDHB in 52 genetically analysed
patients with PPGL who underwent surgery at a large tertiary referral centre. Additional
NGS for patients showing weakly positive SDHB IHC with primarily unknown genetic
status was performed to evaluate the clinical meaning of weakly positive staining.
2. Materials and Methods
Formalin-fixed and paraffin-embedded (FFPE) tumour tissues of PPGL from 230 pa-
tients who underwent surgery at the Thyroid and Endocrine Surgery Centre of Yonsei
Severance Hospital (Seoul, Korea) between 2006 and 2020 were available. Among those
subjects, 52 patients who underwent genetic analysis at diagnosis either through NGS or
direct sequencing of RET, NF1, VHL, and SDHx genes were included. Thirty five patients
received NGS for germline mutation analysis and 17 received direct sequencing for RET,
VHL and NF1. All patients who underwent direct sequencing test had a family history of
pheochromocytoma and other clinical manifestations of MEN type 2 or neurofibroma. On
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the other hand, patients who underwent NGS were apparently sporadic. For additional
analysis of weakly positive staining, 6 genetically untested patients with weakly positive
SDHB IHC had been recalled and undergone NGS. All of these patients showed sporadic
phenotype at diagnosis.
Medical records were retrospectively reviewed. Pheochromocytoma of the adrenal
gland scaled score (PASS) was used to risk stratification. PASS consists of 12 histomorpho-
logical parameters. Tumours with PASS ≥ 4 are considered at high risk of metastasis.
2.1. Tissue Microarray (TMA) Construction
Haematoxylin and eosin (H&E)-stained slides were reviewed and the slide with the
most representative tumour area was selected. Then, the matching FFPE blocks were
collected. In the collected FFPE blocks, representative tumour areas were identified by
contrasting with H&E-stained glass slides, and 3-mm cores were obtained and transferred
to empty paraffin blocks to construct TMA blocks. The TMAs were sectioned in 4-µm slices,
mounted on glass slides, and stained with H&E.
2.2. IHC of SDHB
IHC was performed on 4-µm-thick sections from TMA blocks. IHC was performed
according to the manufacturer’s protocols. Briefly, SDHB staining was performed on an
automated Ventana BenchmarkXT slide stainer (Ventana, Tucson, AZ, USA), using primary
antibodies against SDHB (Abcam, clone 21A11, 1:50). Ultra VIEW Universal DAB Detection
Kit (Ventana/Roche; Tucson, AZ, USA) was used in accordance with the manufacturer’s
instructions. Human adrenal gland tissues were used as positive controls. In the tumour,
the normal stromal cells or endothelial cells or lymphocytes served as an internal positive
control for each sample. The primary antibody was omitted for negative control.
2.3. IHC Interpretation
All immunohistochemically stained slides were interpreted by one experienced en-
docrine pathologist. The pathologist interpreted the IHC slide without any knowledge of
the clinical, pathologic, and molecular data. The interpretation criteria used in this study
followed those reported in a previous study [17]. Briefly, cases with definite granular cyto-
plasmic staining of tumour cells (mitochondrial pattern) were considered positive. Cases
with weak cytoplasmic expression with no granular cytoplasmic staining were classified as
“weakly positive”. As in previous studies of Gill et al., the diffuse quality of the cytoplasmic
staining of the tumour cells was identified in these cases, which was contrasted with the
strong granular staining of internal controls [17]. Cases with focal but definite granular
cytoplasmic staining of tumour cells were also considered positive. Figure 1 shows the
positive, weakly positive, and negative stains for SDHB. The distinction between positive
and weakly positive staining was based on the intensity of staining, not the proportion of
staining. All “weakly positive” slides were reviewed again to confirm the interpretation.
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Figure 1. Positive (A), weakly positive (B), and negative (C) stains for SDHB.
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2.4. Genetic Analysis
Mutation analyses for 52 patients were performed previously. DNA was retrieved
from peripheral blood and isolated using standard procedures. Mutation analyses for RET,
NF1, VHL, and SDHB genes were performed with either commercial sequencing of PCR
products or with endocrine NGS panel of our centre.
2.4.1. Sanger Sequencing
PCR amplification was performed using the in-house primers for RET, NF1, VHL,
and SDHB sequencing, which were designed to amplify exon 10, 11, and 13–16 of RET,
all exons of NF1, coding exons 1, 2, and 3 of VHL, and exon 1–8 of SDHB, respectively.
After PCR-amplified reactions, the PCR products were treated with exonuclease I and
shrimp alkaline phosphatase (USB Corp., Cleveland, OH, USA). Direct sequencing was
performed using a 3730 DNA Analyzer with the BigDye Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems, Foster City, CA, USA). Enzyme reactions and cycle reactions
were carried out according to the manufacturers’ instructions. The results were aligned
against reference sequences (NM_020630.4 for RET, NM_000267.3 for NF1, NM_000551.3
for VHL, and NM_0030002 for SDHB) using the Sequencher 5.3 software (Gene Codes
Corp., Ann Arbor, MI, USA). Identified variants were annotated according to nomenclature
recommendations of the Human Genome Variation Society (HGVS, Available online:
http://www.hgvs.org/mutnomen (accessed on 10 June 2021).
2.4.2. Next Generation Sequencing (NGS)
Genomic DNA extracted from this individual’s sample was used for library prepara-
tion and target capture using a custom panel targeting candidate genes. Massively parallel
sequencing was performed on the NextSeq 550Dx system (Illumina). Quality control
and sequence analysis was performed using our custom analysis pipeline. Copy number
analysis was performed using our custom analysis pipeline. GRCh37 (hg19) was used as
the reference sequence for mapping and variant calling. Databases used for analysis and
variant annotation include Online Mendelian Inheritance in Man (OMIM), Human Gene
Mutation Database (HGMD), ClinVar, dbSNP, 1000 Genome, Exome Aggregation Consor-
tium (ExAC), Exome Sequencing Project (ESP), and Korean Reference Genome Database
(KRGDB). Classification of variants followed the standards and guidelines established by
the American College of Medical Genetics (ACMG). All pathogenic and likely pathogenic
variants were further confirmed by Sanger sequencing. This endocrine NGS panel includes
400 genes, including RET, NF1, VHL, SDHA, SDHAF2, SDHB, SDHC, SDHD, FH, MAX,
and TMEM127 genes.
2.5. Statistical Anlysis
Statistical analysis was performed using SPSS v26.0. χ2 and Fisher exact tests were
used for categorical variables. Student’s t and Mann–Whitney U tests were applied for
continuous variables. Data were considered statistically significant if p ≤ 0.05.
The study protocol was approved by the institutional review board (IRB) of the Yonsei
University College of Medicine (IRB No.4-2019-1089). The research was performed in
accordance with the Declaration of Helsinki. Informed consent was obtained from all
patients.
3. Results
There were 45 adrenal pheochromocytomas and 7 extra-adrenal but intra-abdominal
paragangliomas. All paragangliomas were located in the aortocaval area, which is known
as the organ of Zuckerkandl. There were 45 tumours with PASS < 4 and 7 with PASS ≥ 4.
All SDHx mutations with ACMG class 4 or 5 (n = 11) were found by NGS. Nine
among nine RET mutations, two among four VHL mutations, and two among two NF1
mutations were confirmed by direct sequencing. However, there were four negative results
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of direct sequencing, even though patients had a family history of MEN2 or past history of
hyperparathyroidism. All of these four tumours showed positive SDHB IHC.
The results are presented in Table 1. All the SDHB-negative stained patients had the
SDHB or SDHD mutation. Six of the SDHB mutated tumours were pheochromocytomas
of the adrenal gland scaled score (PASS) ≥ 4. There was no SDHC mutation found in
our cohort. Two of the RET and one of the VHL mutation cases showed weak diffuse
cytoplasmic staining. All 12 remaining tumours were positive for SDHB staining. Of the
remaining 26 patients with no pathogenic mutation in gene studies, three were weakly
positive for SDHB. Except for the weak positive staining category, the sensitivity and
specificity of SDHB IHC for predicting SDHx mutations were both 100%.
Table 1. Clinical and immunohistochemical data on 52 patients who underwent genetic analysis.
Gene Mutated (n) M/F Age (y, Mean) PCC (PASS ≥ 4) PGL (PASS ≥ 4) SDHB IHC Neg/Weak/Pos
SDHB 9 5/4 16–67 (37) 5 (4) 4 (2) 8/1/0
SDHD 2 0/2 24–56 (40) 1 (0) 1 (0) 2/0/0
RET 9 4/5 13–62 (48) 9 (0) 0 0/2/7
VHL 4 3/1 30–55 (48) 3 (0) 1 (0) 0/1/3
NF1 2 1/1 36–55 (52) 2 (0) 0 0/0/2
Unknown 26 10/16 19–68 (49) 25 (1) 1 (0) 0/3/23
Total 52 23/29 13–68 (49) 45 (5) 7 (2) 10/7/35
PCC, pheochromocytoma; PGL, paraganglioma; PASS, pheochromocytoma of the adrenal gland scaled score; neg, negative; weak, weakly
positive; pos, positive.
We performed additional NGS for six patients with weak positive SDHB staining after
we confirmed IHC. All six of them showed no pathogenic germline mutation. These two
cohorts were combined thereafter, and a total of 58 samples from patients with pheochro-
mocytoma or paraganglioma were stained for SDHB (Table 2). In our study, the SDHB IHC
negative group showed a significantly high incidence of high-risk PPGL, with PASS ≥ 4
(p = 0.000).
Table 2. Summary of 58 patients with pheochromocytoma–paraganglioma.
SDHB IHC PASS (n) Gene Mutation
SDHB neg PASS < 4 5 SDHB (3), SDHD (2)
PASS ≥ 4 5 SDHB (5)
SDHB weak
PASS < 4 12 RET (2), VHL (1), unknown (9)
PASS ≥ 4 1 SDHB (1)
SDHB pos PASS < 4 34 RET (7), VHL (3), NF1 (2), unknown (22)
PASS ≥ 4 1 Unknown (1)
Total 58 SDHB (9), SDHD (2), RET (9), VHL (4), NF1 (2), unknown (32)
Neg, negative; weak, weakly positive; pos, positive; PASS, pheochromocytoma of the adrenal gland scaled score.
4. Discussion
In our first study in South Korea, the results of IHC for SDHB were consistent with
those of previous studies. Ten patients with SDHB-negative IHC had SDHx mutations.
Meanwhile, there were three patients who showed weak positive staining and who had
RET or VHL mutations. These intermediate patterns that associated with other germline
mutations rather than SDH mutations have been reported by other groups as well [17,22,23].
Previous studies assumed that this might be due to the low concentration of SDHB antibody
in the IHC protocol, and it might be correlated with SDHD and VHL mutations [17,23].
However, in our study, patients with RET mutation and no pathogenic germline mutations
also showed weak positive staining. This may be explained by false negative results of
genetic screening or unknown germline mutations. There was no SDHx mutation found in
the SDHB-positive group.
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SDHB mutation is known to correlate with metastatic disease, which is supported by
our results. Blank et al. demonstrated that the loss of SDHB can predict metastasis in PPGL,
but there was a lack of association with classic hypoxia signalling, which is known to cause
malignant PPGL [24]. Although the mechanism of developing malignant PPGL has not yet
been identified, the authors suggested more rigorous follow-up of SDHB-negative tumours
due to correlation between the loss of SDHB and adverse outcomes [24].
The detection of hereditary PPGL is important for patients as well as their family mem-
bers, as it increases the risk of developing various multiple and metastatic neoplasms [6].
Mutation analysis for SDH genes combined with RET and VHL gene tests is known to cost
up to USD 4100 in the US [25]. Although this might decrease with the adoption of an NGS
panel, balancing between risk reduction and financial cost is still an important issue. In this
respect, several attempts have been made to develop tools for triaging genetic screening.
Meticulous history taking about correlated conditions in syndromic diseases with physical
examination, including the typical cutaneous café-au-lait spot in neurofibromatosis type 1,
and drawing the familial pedigree can help guide subsequent genetic testing. However,
there are no reliable phenotypic differences between sporadic PPGL and hereditary PPGL,
which is non-syndromic in nature and caused by germline mutations of SDHB, SDHC, and
SDHD genes. For this reason, the WHO recommends genetic testing for all patients even
without family history, depending on local resources [21]. A targeted NGS panel has been
suggested as a feasible alternative to previous whole exome sequencing for genetic analysis
due to its cost-effective nature and easy instrumentation [26]. However, finding an effective
way to detect SDHx mutations which can help pre-screening will greatly contribute to a
further reduction in medical costs and treating hereditary PPGL, especially in developing
countries.
SDHA, SDHB, SDHC, and SDHD are encoded by SDHA, SDHB, SDHC, and SDHD
genes, respectively, and these proteins are assembled in the mitochondria to form the
mitochondrial complex II (succinate dehydrogenase), which acts as a key respiratory en-
zyme as well as an intracellular oxygen sensor [27,28]. It has been demonstrated that the
inactivation of any of the SDH genes causes functional loss of SDH enzymatic activity,
destabilisation, and proteolysis of complex II [17,28]. Thus, the presence of biallelic inacti-
vation of SDH decreases SDHB expression, which can be identified with simple and cheap
immunohistochemical staining. The usefulness of IHC staining of SDHB before genetic
testing has been validated by many groups. IHC can detect germline SDHx mutations with
high sensitivity and specificity [8,17]. A three-tiered grading system reported by Gill et al.
contributed to increasing the concordance between interobservers [17]. This was further
validated by Papathomas et al. with a multinational study [20]. The results of our study
also support these previous studies.
However, there are still debates on the interpretation of weakly positive SDHB staining.
Menara et al. suggested that further SDHD IHC can help diagnose SDHx mutations in
the case of weak diffuse SDHB IHC [19]. There were a total of 13 weakly positive SDHB
IHC cases in our cohort. Except three patients who had RET or VHL mutations confirmed
by direct sequencing and one patient with SDHB mutation confirmed by NGS, the rest
of the nine patients who underwent NGS had only ACMG class 3, a variant of unknown
significance. According to our study, the possibility of other germline mutations such as
RET and VHL (23%) or negative (or not-yet-known) germline mutations (69%) is higher
than that of SDHx mutations (8%) when SDHB IHC is weakly positive. Therefore, an
additional genetic study would be more helpful than SDHD IHC in the case of weakly
positive SDHB IHC.
This study has several limitations. First, it is a retrospective study with small sample
numbers. As PPGLs are rare tumours and only those patients who underwent endocrine
surgery in the department were included, only 230 patients were screened. As referrals
in our centre have been dependent on the location of PPGL, several surgical departments,
such as urological surgery, hepatobiliary surgery, neurosurgery, and endocrine surgery,
have been involved in the treatment of PPGL. This explains the zero incidence of carotid
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body paraganglioma and bladder paraganglioma in our study, which has been presented
in another study [17]; this could have led to selection bias.
Second, not all the screened patients had undergone genetic analysis. After the
exclusion of the genetically untested patients, only 58 patients were enrolled. The cost of
an NGS panel for endocrine disease in our centre is approximately USD 4000. Before NGS
was introduced, direct sequencing had been used for genetic analysis and it costs about
USD 200 per gene. However, not all genes recommended for testing in a recent consensus
were available for analysis, such as FH, MAX, and TMEM127 [29]. Although this is cheaper
than the cost in the US, the cost is still high and it is a barrier for gene study, especially in
the case of patients without medical insurance coverage. Many patients are reluctant to
participate in genetic studies because of the sporadic and benign nature of their tumours.
The adoption of a target NGS panel specified for PPGL could be helpful to encourage more
patients to undergo genetic analysis.
Third, the heterogeneity of the gene study method can also be considered a limitation
of this study. As most of the direct sequencing has been performed on single genes
according to the family history and correlated symptoms of patients, another untested
germline mutation could be neglected. Further large multicentre studies with homogenous
multigene screening methods are needed.
Fourth, there is an absence of comparison data with tissue or healthy control samples
to confirm germline mutations. Although all mutation analyses have been performed with
peripheral blood, this fact alone does not guarantee that all genetic mutations found are
germline mutations. However, according to a previous study, genetic mutations in PPGL
were almost always associated with germline mutations [17]. Therefore, it can be expected
that the mutations found in our study are highly likely germline mutations.
5. Conclusions
Despite the above limitations, this is the first study to examine SDHB IHC in PPGL
tissues in South Korea, which can add information about the interpretation of weakly
positive staining of SDHB. Although immunohistochemistry alone cannot replace genetic
evaluation, SDHB IHC can be a reliable and cost-effective preliminary method to screen
SDHx mutations. Especially in the case of weakly positive staining of SDHB, an additional
study should be considered to rule out SDHx or another germline mutation.
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